Considering the differential expression of BRD4 between tumor and normal tissues, we further propose that t BET inhibition might serve as a potential alternative to conventional genotoxic agents like cisplatin, which induces non-specific DNA cross-links (46, 47). Here, BRD4 is linked to neoplasm.